Possible correlated signaling pathways with chronic urate nephropathy: A review.
Li K, Ma Y, Xia X, Huang H, Li J, Wang X, Gao Y, Zhang S, Fu T, Tong Y.
Medicine (Baltimore). 2023 Aug 11;102(32):e34540. doi: 10.1097/MD.0000000000034540.
Kidney stones.
Khan SR, Pearle MS, Robertson WG, Gambaro G, Canales BK, Doizi S, Traxer O, Tiselius HG.
Nat Rev Dis Primers. 2016 Feb 25;2:16008. doi: 10.1038/nrdp.2016.8.
Urate-Lowering Therapy and Chronic Kidney Disease Progression.
Feig DI.
N Engl J Med. 2020 Jun 25;382(26):2567-2568. doi: 10.1056/NEJMe2015886.
Uric Acid and Oxidative Stress-Relationship with Cardiovascular, Metabolic, and Renal Impairment.
Gherghina ME, Peride I, Tiglis M, Neagu TP, Niculae A, Checherita IA.
Int J Mol Sci. 2022 Mar 16;23(6):3188. doi: 10.3390/ijms23063188.
Uric acid and the kidney.
Fathallah-Shaykh SA, Cramer MT.
Pediatr Nephrol. 2014 Jun;29(6):999-1008. doi: 10.1007/s00467-013-2549-x. Epub 2013 Jul 4.
A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease.
Yanai H, Adachi H, Hakoshima M, Iida S, Katsuyama H.
Cells. 2024 Mar 4;13(5):450. doi: 10.3390/cells13050450.
Normal and pathologic concentrations of uremic toxins.
Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A; European Uremic Toxin Work Group.
J Am Soc Nephrol. 2012 Jul;23(7):1258-70. doi: 10.1681/ASN.2011121175. Epub 2012 May 24.
AMP-activated protein kinase alpha2 contributes to acute and chronic hyperuricemic nephropathy via renal urate deposition in a mouse model.
Yang C, Su HY, An N, Wu HL, Guo XY, Li ZH, Chen XC, Zhu SP, Wu D, Li HY, Pan QJ, Liang D, Liu HF.
Eur J Med Res. 2022 Sep 10;27(1):176. doi: 10.1186/s40001-022-00800-1.
Hyperuricemia: An Intriguing Connection to Metabolic Syndrome, Diabetes, Kidney Disease, and Hypertension.
Vareldzis R, Perez A, Reisin E.
Curr Hypertens Rep. 2024 Jun;26(6):237-245. doi: 10.1007/s11906-024-01295-3. Epub 2024 Jan 25.
The SGLT2 inhibitor dapagliflozin ameliorates renal fibrosis in hyperuricemic nephropathy.
Hu H, Li W, Hao Y, Peng Z, Zou Z, Wei J, Zhou Y, Liang W, Cao Y.
Cell Rep Med. 2024 Aug 20;5(8):101690. doi: 10.1016/j.xcrm.2024.101690.
